In view of emerging Th17-IL-17 targeted therapies in spondyloarthropathies (ustekinumab, antibody to common p40 subunit of IL12 and IL-23; secukinumab, antibody to IL-17A; brodalumab, antibody to IL-17 receptor antagonist) [25], our findings of increased IL-17 and IL-23 in TA offer potential newer therapeutic approaches in refractory TA. This evidence concerns the gene IL17A and Takayasu arteritis.